Latest Astex Pharmaceuticals Inc (ASTX) Headlines
SIAST Students Benefit from Hands-on Experience Thanks to Harper Government
Marketwire - Mon Mar 10, 11:01AM CDT
Western Economic Diversification Canada
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Astex Earns Milestone Payment on Initiation of Phase 3 Study
Business Wire - Tue Mar 04, 3:00PM CST
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has received a milestone payment triggered by the commencement, by Novartis, of a Phase 3 study of LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6. LEE011 was discovered as part of a drug discovery collaboration between Astex and Novartis announced in December 2005.
Shell to stop Alaska exploratory drilling in 2014
EFE News Services - Thu Jan 30, 1:22PM CST
Royal Dutch Shell will halt its exploration program for the U.S. state of Alaska in 2014, new CEO Ben van Beurden announced Thursday.
2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018
M2 - Fri Jan 24, 4:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/rbvt8k/epigenetics_drugs) has announced the addition of the "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018" report to their offering. "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018", on the epigenetics drugs and diagnostic technologies market provides detailed analysis of the global market and helps in understanding the driving forces for the growth of these technologies. The report also provides analysis of the drugs market by the mechanism of its action namely, DNMT inhibitors and HDAC inhibitors. The report also discusses the diagnostic technologies market by types which include DNA methylation and ChIP (Chromatin Immunoprecipitation) technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each segment and sub-segment, in terms of USD million, using 2010 as the base year. The market has also been segmented geographically into four regions namely North America, Europe, Asia-Pacific, and Rest of the World (RoW). Market size and forecast has been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the epigenetics market and future opportunities are provided in the report. Competitive landscape and end user analysis for the product types is highlighted and the market players are profiled with attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. The global epigenetics drugs and diagnostic technologies market is segmented into the following categories: - Epigenetics Drugs Market, by Mechanism of Action - DNMT Inhibitors - Azacitidine (Vidaza) - Decitabine (Dacogen - HDAC Inhibitors - Vorinostat (Zolinza - Romidepsin (Istodax) - Epigenetics Diagnostic Technologies Market, by Types - DNA Methylation - Chromatin Immunoprecipitation (ChIP) Technology Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Epigenetics Drugs Market, By Mechanism Of Action 5 Epigenetics Diagnostic Technology Market, By Types 6 Global Epigenetics Technologies Market, By Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - 4SC - Acetylon Pharmaceuticals - Astex Pharmaceuticals - Celgene Corporation - Cellcentric - Celleron Therapeutics - Chroma Therapeutics - Eisai - Envivo Pharmaceuticals - Epigentek Group - Epizyme - Illumina - Mdxhealth - Merck & Company - Novartis International - Oncolys Biopharma - Pharmacyclics - Repligen Corporation - Spectrum Pharmaceuticals - Syndax Pharmaceuticals - Topotarge - Valirx For more information visit http://www.researchandmarkets.com/research/rb...tics_drugs
2013 Report on the International Solid State Lighting Market - Analysis & Forecast to 2018
M2 - Wed Jan 15, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/lw4wz8/solid_state) has announced the addition of the "2013 Report on the International Solid State Lighting Market - Analysis & Forecast to 2018" report to their offering. The development of technologies such as optoelectronics has revolutionized the lighting market. Environmental concerns are driving the low-power-consuming lighting systems, and therefore most of the recent developments in the lighting market aim at providing more energy-efficient products that give higher light output at less power consumption. This report provides detail analysis on various types of material used at different levels such as LED at Die level, Package level, Module level and Luminaries level. The different applications of solid state lighting are also discussed that includes: general lighting, back lighting, automotive lighting and medical lighting. The study describes the deployment of Solid State Lighting technologies at different verticals which include the automotive & transportation industry, residential & offices, consumer electronics, and industrial sector. The total market is expected to reach $56.79billion by 2018, at a CAGR of 18.7% from 2013 to 2018. APAC leads the overall global Solid State Lighting market for the largest percentage share with 49.8% in 2012. North America and Europe follows the APAC region with 23.9% and 19.9% of the overall SSL market respectively. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Cover Story 4 Market Overview 5 Industry Analysis 6 Market Analysis 7 Solid State Lighting, By Materials 8 Solid State Lighting Market, By Types 9 Solid State Lighting Market, By Applications 10 Solid State Lighting Market, By Verticals 11 Solid State Lighting Market, By Geography 12 Competitive Landscape 13 Company Profiles Companies Mentioned: - Advanced Lighting Technologies - Aixtron Se - Applied Materials - Applied Science And Technology Research Institute (ASTRI) Company - Bridgelux, Inc - Cambridge Display Technology - Citizen Electronics Co - Cree - Energy Focus - Everlight Electronics Co - Fairchild Semiconductor International - Ge Lighting Co - Intematix Corporation - Led Engin - Lg Innotek - Lustrous Technology - Mitsubishi Electric Corporation - Nichia Corporation - Osram Licht Ag - Panasonic Corporation - Royal Philips Electronics NV - Samsung Led Co - Seoul Semiconductor Co - Tcp - Toyoda Gosei Co - Tridonic Gmbh& Co Kg - Veeco Instruments For more information visit http://www.researchandmarkets.com/research/lw...olid_state
KineMed Announces the Hire of Timothy Enns as Chief Investor and Media Relations Officer
Business Wire - Mon Jan 13, 4:59AM CST
KineMed, Inc. (www.kinemed.com) announced today that Timothy L. Enns has been hired as Chief Investor and Media Relations Officer. Mr. Enns most recently served as SVP of Corporate Communications and Marketing for Astex Pharmaceuticals (NASDAQ: ASTX), (formerly SuperGen, Inc. (SUPG)), which was acquired by Otsuka Pharmaceuticals. Mr. Enns held various senior management, communication and commercial positions with Astex. Prior to Astex, Mr. Enns held positions at Sequus Pharmaceuticals, Trilex Therapeutics, Syncor International, MGI Pharma, Adria Laboratories and The Upjohn Company.
Global Epigenetics Drugs And Diagnostic Technologies Market Report 2013 - 2018
M2 - Mon Nov 25, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pvnggf/epigenetics_drugs) has announced the addition of the "Global Epigenetics Drugs And Diagnostic Technologies Market Report 2013 - 2018" report to their offering. This concise analysis discusses the diagnostic technologies market by types which include DNA methylation and ChIP (Chromatin Immunoprecipitation) technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each segment and sub-segment, in terms of USD million, using 2010 as the base year. The global epigenetics drugs and diagnostic technologies market has also been segmented geographically into four regions namely North America, Europe, Asia-Pacific, and Rest of the World (RoW). Market size and forecast has been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the epigenetics market and future opportunities are provided in the report. The global epigenetics drugs and diagnostic technologies market is segmented into the following categories: - Epigenetics Drugs Market, by Mechanism of Action - DNMT Inhibitors - Azacitidine (Vidaza) - Decitabine (Dacogen - HDAC Inhibitors - Vorinostat (Zolinza - Romidepsin (Istodax) - Epigenetics Diagnostic Technologies Market, by Types - DNA Methylation - Chromatin Immunoprecipitation (ChIP) Technology Epigenetics Technologies Market, by Geography - North America - Europe - Asia-Pacific Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Drivers 3.3 Market Restraints 3.4 Market Opportunities 3.5 Porter's Five Forces Analysis 3.6 Market Attractiveness Analysis 4 Epigenetics Drugs Market, By Mechanism Of Action 5 Epigenetics Diagnostic Technology Market, By Types 6 Global Epigenetics Technologies Market, By Geography 6.1 Overview 6.2 Comparative Analysis: Epigenetic Technologies Market, By Geography, 2011 & 2018 (Value %) 6.3 North America 6.4 Europe 6.5 Asia-Pacific 6.6 Rest of the World 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned - 4SC AG - Acetylon Pharmaceuticals, Inc. - Astex Pharmaceuticals Inc. - Celgene Corporation - Cellcentric Ltd. - Celleron Therapeutics Ltd. - Chroma Therapeutics Ltd. - Eisai Co. Ltd. - Envivo Pharmaceuticals Inc. - Epigentek Group Inc. - Epizyme, Inc. - Illumina Inc. - Mdxhealth - Merck & Company Inc. - Novartis International AG - Oncolys Biopharma Inc. - Pharmacyclics, Inc. - Repligen Corporation - Spectrum Pharmaceuticals - Syndax Pharmaceuticals, Inc. - Topotarget A/S - Valirx Plc For more information visit http://www.researchandmarkets.com/research/pv...tics_drugs
Global Solid State Lighting Market to 2018: LED, OLED, and PLED
M2 - Thu Nov 21, 9:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/jht5zl/solid_state) has announced the addition of the "Global Solid State Lighting Market to 2018: LED, OLED, and PLED" report to their offering. The increasing demand for energy-saving and environment-friendly lighting technology is driving the growth of the global solid state and other energy efficient lighting systems market. The development of technologies such as optoelectronics has revolutionized the lighting market. Environmental concerns are driving the low-power-consuming lighting systems, and therefore most of the recent developments in the lighting market aim at providing more energy-efficient products that give higher light output at less power consumption. The market is segmented in three categories namely: LED, OLED and PLED. This report provides detail analysis on various types of material used at different levels such as LED at Die level, Package level, Module level and Luminaries level. The different applications of solid state lighting are also discussed that includes: general lighting, back lighting, automotive lighting and medical lighting. The study describes the deployment of Solid State Lighting technologies at different verticals which include the automotive & transportation industry, residential & offices, consumer electronics, and industrial sector. Complimentary technologies market that aid lighting industry such as eco-friendly and non eco-friendly technologies are provided in the report. Value chain analysis, product lifecycle and cost benefit analysis are also briefly explained. Geographical regions covered include North America, Europe, APAC and ROW. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Cover Story 4 Market Overview 5 Industry Analysis 6 Market Analysis 7 Solid State Lighting, By Materials 8 Solid State Lighting Market,By Types 9 Solid State Lighting Market, By Applications 10 Solid State Lighting Market, By Verticals 11 Solid State Lighting Market, By Geography (Page No. - 206) 12 Competitive Landscape 13 Company Profiles - Advanced Lighting Technologies, Inc - Aixtron Se - Applied Materials, Inc - Applied Science And Technology Research Institute (ASTRI) Company Ltd - Bridgelux, Inc - Cambridge Display Technology Ltd - Citizen Electronics Co, Ltd - Cree, Inc - Energy Focus, Inc - Everlight Electronics Co, Ltd - Fairchild Semiconductor International, Inc - Ge Lighting Co - Intematix Corporation - Led Engin, Inc - Lg Innotek, Co Ltd - Lustrous Technology, Ltd - Mitsubishi Electric Corporation - Nichia Corporation - Osram Licht Ag - Panasonic Corporation - Royal Philips Electronics NV - Samsung Led Co, Ltd - Seoul Semiconductor Co, Ltd - Tcp, Inc - Toyoda Gosei Co, Ltd - Tridonic Gmbh& Co Kg - Veeco Instruments, Inc For more information visit http://www.researchandmarkets.com/research/jh...olid_state About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SIAST gets $1.125 million boost from Husky Energy
CNW Group - Wed Nov 20, 10:00AM CST
Innovative partnership helping to build skilled trades capacity
Personalized Medicine and Companion Diagnostic Market Q3 2013 research Report
M2 - Tue Nov 05, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s677dt/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market Q3 2013 - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report to their offering. 'Personalized Medicine and Companion Diagnostic Market Q3 2013 - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment' is a cutting-edge comprehensive report on the personalized medicine industry and its impact on the health system. This report tackles the growing market interest in pharmacogenomics, companion diagnostics and the associated market environment. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analysed. This study reveals market figures of the overall personalized medicine market and also sub-market figures. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the personalized medicine industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. In summary, the personalized medicine and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: Executive Summary Introduction Personalized Medicine Therapeutics and Companion Diagnostics Personalized Medicine and Integration into the Healthcare System Private and Public Funding and Personalized Medicine Reimbursement European Personalized Medicine Market - Payments and Investment Personalized Medicine -Business Model Analysis Personalized Medicine Main Industry Players Personalized Medicine Industry Products and Kits Personalized Medicine Market Analysis Strengths and Advantages of Personalized Medicine Restraints of the Personalized Medicine Market Personalized Medicine and Regulatory Policies Final Summary and Future Perspectives List of Tables List of Figures Companies Mentioned - 23andMe - Affymetrix - Astex Pharmaceuticals - Atossa Genetics - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Illumina - Genelex - Myriad - Nodality - Qiagen For more information visit http://www.researchandmarkets.com/research/s6...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Astex Pharmaceuticals to Present at AACR-NCI-EORTC
GlobeNewswire - Mon Oct 14, 3:30PM CDT
Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced four presentations of developmental and collaboration programs will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 20 and 21, in Boston.
Otsuka Pharmaceutical Co Ltd acquires Astex Pharmaceuticals for USD8.50 per share
M2 - Mon Oct 14, 5:50AM CDT
Otsuka Holdings Co Ltd reported on Friday the completion of the acquisition of Astex Pharmaceuticals Inc (NasdaqGS:ASTX) for USD8.50 per share, net to the seller in cash, without interest and less any required withholding taxes.
Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals
Business Wire - Fri Oct 11, 7:31AM CDT
Otsuka Holdings Co., Ltd. ("Otsuka Holdings") announced today that its wholly-owned subsidiary, Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"), successfully completed, through its wholly-owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex") for US $8.50 per share, net to the seller in cash, without interest and less any required withholding taxes. The acquisition was effected through a tender offer ("Tender Offer"), which was commenced on September 13, 2013, New York time and expired at 12:00 midnight, New York time at the end of October 10, 2013, followed by a merger on October 11, 2013.
Astex Pharmaceuticals Responds to Further Misleading Claims Made by Sarissa Capital
GlobeNewswire - Wed Oct 09, 9:37PM CDT
Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, issued the following statement in response to further misleading claims made by Sarissa Capital in a press release issued earlier today:
Sarissa Capital Highlights Advancement Of Astex Pipeline Compound
PR Newswire - Wed Oct 09, 4:27PM CDT
Sarissa Capital today issued the following open letter to shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX):
Sarissa Capital Urges All Shareholders Of Astex Pharmaceuticals To Not Tender Their Shares At Current $8.50 Price
PR Newswire - Tue Oct 08, 12:33PM CDT
Sarissa Capital today issued the following open letter to shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX):
Astex Pharmaceuticals Announces Expiration of HSR Waiting Period for Pending Transaction
GlobeNewswire - Mon Oct 07, 5:00AM CDT
Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), announced today that the waiting period for U.S. antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the previously announced acquisition of Astex by Otsuka Pharmaceutical Co., Ltd ("Otsuka"), expired on Friday, October 4, 2013. Expiration of the waiting period satisfies a condition to the closing of the tender offer by Otsuka for all of the outstanding shares of Astex common stock for $8.50 per share in cash, which is scheduled to expire at 12:00 AM ET on October 10, 2013, unless extended or earlier terminated. The closing of the tender offer remains subject to other customary closing conditions, including, among others, the tender into the offer by the holders of a majority of the outstanding shares of Astex.
SIAST Students Benefit from Hands-on Experience Thanks to Harper Government
Marketwire - Mon Mar 10, 11:01AM CDT
Western Economic Diversification Canada
Personalized Medicine and Companion Diagnostic Market - 2014 Gives Details of their Operations, Products, Financials and Business Strategy
M2 - Thu Mar 06, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpc89x/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 263 tables & figures over 224 pages. The personalized medicine (global) market is presented as follows: -By Company -By Geography -By Segment -By Sub-market A wealth of financial data & business strategy information is provided including: -Up-to-date company financials, sales & revenue figures -Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies -Business Model Strategies for Providers. Provider Systems and Academic Medical Centres -Business Model Strategies for Payers & Governments -Private and Public Funding and Personalized Medicine Reimbursement -Revisions to Current Payment Systems and intellectual property -How to Gain Market Penetration in the EU -Cost-effectiveness and Business Value of Personalized Medicine -Consumer genomics and POC market -Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) -Comprehensive account of company product portfolios & kits This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy. -23andMe -Affymetrix -Astex Pharmaceuticals -Atossa Genetics -CuraGen -Celera Corporation (Quest Diagnostics) -Celldex Therapeutics -deCode Genetics (Amgen) -Illumina -Genelex -Myriad -Nodality -Qiagen This report tackles key concerns to the personalized medicine market such as: -Lack of regulatory policy and legislation in the US and Europe -Reimbursement schemes and payers concerns -Transition of investigational diagnostic assays and therapeutics to clinical practice -Direct to consumer (DTC) test kits and implications for the public This detailed report is supported with 263 figures and tables over 224 pages and profiles the main pharmacos in personalized medicine. For more information visit http://www.researchandmarkets.com/research/rp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Astex Earns Milestone Payment on Initiation of Phase 3 Study
Business Wire - Tue Mar 04, 3:00PM CST
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has received a milestone payment triggered by the commencement, by Novartis, of a Phase 3 study of LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6. LEE011 was discovered as part of a drug discovery collaboration between Astex and Novartis announced in December 2005.
Shell to stop Alaska exploratory drilling in 2014
EFE News Services - Thu Jan 30, 1:22PM CST
Royal Dutch Shell will halt its exploration program for the U.S. state of Alaska in 2014, new CEO Ben van Beurden announced Thursday.
2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018
M2 - Fri Jan 24, 4:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/rbvt8k/epigenetics_drugs) has announced the addition of the "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018" report to their offering. "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018", on the epigenetics drugs and diagnostic technologies market provides detailed analysis of the global market and helps in understanding the driving forces for the growth of these technologies. The report also provides analysis of the drugs market by the mechanism of its action namely, DNMT inhibitors and HDAC inhibitors. The report also discusses the diagnostic technologies market by types which include DNA methylation and ChIP (Chromatin Immunoprecipitation) technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each segment and sub-segment, in terms of USD million, using 2010 as the base year. The market has also been segmented geographically into four regions namely North America, Europe, Asia-Pacific, and Rest of the World (RoW). Market size and forecast has been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the epigenetics market and future opportunities are provided in the report. Competitive landscape and end user analysis for the product types is highlighted and the market players are profiled with attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. The global epigenetics drugs and diagnostic technologies market is segmented into the following categories: - Epigenetics Drugs Market, by Mechanism of Action - DNMT Inhibitors - Azacitidine (Vidaza) - Decitabine (Dacogen - HDAC Inhibitors - Vorinostat (Zolinza - Romidepsin (Istodax) - Epigenetics Diagnostic Technologies Market, by Types - DNA Methylation - Chromatin Immunoprecipitation (ChIP) Technology Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 4 Epigenetics Drugs Market, By Mechanism Of Action 5 Epigenetics Diagnostic Technology Market, By Types 6 Global Epigenetics Technologies Market, By Geography 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - 4SC - Acetylon Pharmaceuticals - Astex Pharmaceuticals - Celgene Corporation - Cellcentric - Celleron Therapeutics - Chroma Therapeutics - Eisai - Envivo Pharmaceuticals - Epigentek Group - Epizyme - Illumina - Mdxhealth - Merck & Company - Novartis International - Oncolys Biopharma - Pharmacyclics - Repligen Corporation - Spectrum Pharmaceuticals - Syndax Pharmaceuticals - Topotarge - Valirx For more information visit http://www.researchandmarkets.com/research/rb...tics_drugs
2013 Report on the International Solid State Lighting Market - Analysis & Forecast to 2018
M2 - Wed Jan 15, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/lw4wz8/solid_state) has announced the addition of the "2013 Report on the International Solid State Lighting Market - Analysis & Forecast to 2018" report to their offering. The development of technologies such as optoelectronics has revolutionized the lighting market. Environmental concerns are driving the low-power-consuming lighting systems, and therefore most of the recent developments in the lighting market aim at providing more energy-efficient products that give higher light output at less power consumption. This report provides detail analysis on various types of material used at different levels such as LED at Die level, Package level, Module level and Luminaries level. The different applications of solid state lighting are also discussed that includes: general lighting, back lighting, automotive lighting and medical lighting. The study describes the deployment of Solid State Lighting technologies at different verticals which include the automotive & transportation industry, residential & offices, consumer electronics, and industrial sector. The total market is expected to reach $56.79billion by 2018, at a CAGR of 18.7% from 2013 to 2018. APAC leads the overall global Solid State Lighting market for the largest percentage share with 49.8% in 2012. North America and Europe follows the APAC region with 23.9% and 19.9% of the overall SSL market respectively. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Cover Story 4 Market Overview 5 Industry Analysis 6 Market Analysis 7 Solid State Lighting, By Materials 8 Solid State Lighting Market, By Types 9 Solid State Lighting Market, By Applications 10 Solid State Lighting Market, By Verticals 11 Solid State Lighting Market, By Geography 12 Competitive Landscape 13 Company Profiles Companies Mentioned: - Advanced Lighting Technologies - Aixtron Se - Applied Materials - Applied Science And Technology Research Institute (ASTRI) Company - Bridgelux, Inc - Cambridge Display Technology - Citizen Electronics Co - Cree - Energy Focus - Everlight Electronics Co - Fairchild Semiconductor International - Ge Lighting Co - Intematix Corporation - Led Engin - Lg Innotek - Lustrous Technology - Mitsubishi Electric Corporation - Nichia Corporation - Osram Licht Ag - Panasonic Corporation - Royal Philips Electronics NV - Samsung Led Co - Seoul Semiconductor Co - Tcp - Toyoda Gosei Co - Tridonic Gmbh& Co Kg - Veeco Instruments For more information visit http://www.researchandmarkets.com/research/lw...olid_state
KineMed Announces the Hire of Timothy Enns as Chief Investor and Media Relations Officer
Business Wire - Mon Jan 13, 4:59AM CST
KineMed, Inc. (www.kinemed.com) announced today that Timothy L. Enns has been hired as Chief Investor and Media Relations Officer. Mr. Enns most recently served as SVP of Corporate Communications and Marketing for Astex Pharmaceuticals (NASDAQ: ASTX), (formerly SuperGen, Inc. (SUPG)), which was acquired by Otsuka Pharmaceuticals. Mr. Enns held various senior management, communication and commercial positions with Astex. Prior to Astex, Mr. Enns held positions at Sequus Pharmaceuticals, Trilex Therapeutics, Syncor International, MGI Pharma, Adria Laboratories and The Upjohn Company.
Global Epigenetics Drugs And Diagnostic Technologies Market Report 2013 - 2018
M2 - Mon Nov 25, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pvnggf/epigenetics_drugs) has announced the addition of the "Global Epigenetics Drugs And Diagnostic Technologies Market Report 2013 - 2018" report to their offering. This concise analysis discusses the diagnostic technologies market by types which include DNA methylation and ChIP (Chromatin Immunoprecipitation) technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each segment and sub-segment, in terms of USD million, using 2010 as the base year. The global epigenetics drugs and diagnostic technologies market has also been segmented geographically into four regions namely North America, Europe, Asia-Pacific, and Rest of the World (RoW). Market size and forecast has been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the epigenetics market and future opportunities are provided in the report. The global epigenetics drugs and diagnostic technologies market is segmented into the following categories: - Epigenetics Drugs Market, by Mechanism of Action - DNMT Inhibitors - Azacitidine (Vidaza) - Decitabine (Dacogen - HDAC Inhibitors - Vorinostat (Zolinza - Romidepsin (Istodax) - Epigenetics Diagnostic Technologies Market, by Types - DNA Methylation - Chromatin Immunoprecipitation (ChIP) Technology Epigenetics Technologies Market, by Geography - North America - Europe - Asia-Pacific Key Topics Covered: 1 Preface 2 Executive Summary 3 Market Overview 3.1 Introduction 3.2 Market Drivers 3.3 Market Restraints 3.4 Market Opportunities 3.5 Porter's Five Forces Analysis 3.6 Market Attractiveness Analysis 4 Epigenetics Drugs Market, By Mechanism Of Action 5 Epigenetics Diagnostic Technology Market, By Types 6 Global Epigenetics Technologies Market, By Geography 6.1 Overview 6.2 Comparative Analysis: Epigenetic Technologies Market, By Geography, 2011 & 2018 (Value %) 6.3 North America 6.4 Europe 6.5 Asia-Pacific 6.6 Rest of the World 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned - 4SC AG - Acetylon Pharmaceuticals, Inc. - Astex Pharmaceuticals Inc. - Celgene Corporation - Cellcentric Ltd. - Celleron Therapeutics Ltd. - Chroma Therapeutics Ltd. - Eisai Co. Ltd. - Envivo Pharmaceuticals Inc. - Epigentek Group Inc. - Epizyme, Inc. - Illumina Inc. - Mdxhealth - Merck & Company Inc. - Novartis International AG - Oncolys Biopharma Inc. - Pharmacyclics, Inc. - Repligen Corporation - Spectrum Pharmaceuticals - Syndax Pharmaceuticals, Inc. - Topotarget A/S - Valirx Plc For more information visit http://www.researchandmarkets.com/research/pv...tics_drugs
Global Solid State Lighting Market to 2018: LED, OLED, and PLED
M2 - Thu Nov 21, 9:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/jht5zl/solid_state) has announced the addition of the "Global Solid State Lighting Market to 2018: LED, OLED, and PLED" report to their offering. The increasing demand for energy-saving and environment-friendly lighting technology is driving the growth of the global solid state and other energy efficient lighting systems market. The development of technologies such as optoelectronics has revolutionized the lighting market. Environmental concerns are driving the low-power-consuming lighting systems, and therefore most of the recent developments in the lighting market aim at providing more energy-efficient products that give higher light output at less power consumption. The market is segmented in three categories namely: LED, OLED and PLED. This report provides detail analysis on various types of material used at different levels such as LED at Die level, Package level, Module level and Luminaries level. The different applications of solid state lighting are also discussed that includes: general lighting, back lighting, automotive lighting and medical lighting. The study describes the deployment of Solid State Lighting technologies at different verticals which include the automotive & transportation industry, residential & offices, consumer electronics, and industrial sector. Complimentary technologies market that aid lighting industry such as eco-friendly and non eco-friendly technologies are provided in the report. Value chain analysis, product lifecycle and cost benefit analysis are also briefly explained. Geographical regions covered include North America, Europe, APAC and ROW. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Cover Story 4 Market Overview 5 Industry Analysis 6 Market Analysis 7 Solid State Lighting, By Materials 8 Solid State Lighting Market,By Types 9 Solid State Lighting Market, By Applications 10 Solid State Lighting Market, By Verticals 11 Solid State Lighting Market, By Geography (Page No. - 206) 12 Competitive Landscape 13 Company Profiles - Advanced Lighting Technologies, Inc - Aixtron Se - Applied Materials, Inc - Applied Science And Technology Research Institute (ASTRI) Company Ltd - Bridgelux, Inc - Cambridge Display Technology Ltd - Citizen Electronics Co, Ltd - Cree, Inc - Energy Focus, Inc - Everlight Electronics Co, Ltd - Fairchild Semiconductor International, Inc - Ge Lighting Co - Intematix Corporation - Led Engin, Inc - Lg Innotek, Co Ltd - Lustrous Technology, Ltd - Mitsubishi Electric Corporation - Nichia Corporation - Osram Licht Ag - Panasonic Corporation - Royal Philips Electronics NV - Samsung Led Co, Ltd - Seoul Semiconductor Co, Ltd - Tcp, Inc - Toyoda Gosei Co, Ltd - Tridonic Gmbh& Co Kg - Veeco Instruments, Inc For more information visit http://www.researchandmarkets.com/research/jh...olid_state About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SIAST gets $1.125 million boost from Husky Energy
CNW Group - Wed Nov 20, 10:00AM CST
Innovative partnership helping to build skilled trades capacity
Personalized Medicine and Companion Diagnostic Market Q3 2013 research Report
M2 - Tue Nov 05, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/s677dt/personalized) has announced the addition of the "Personalized Medicine and Companion Diagnostic Market Q3 2013 - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report to their offering. 'Personalized Medicine and Companion Diagnostic Market Q3 2013 - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment' is a cutting-edge comprehensive report on the personalized medicine industry and its impact on the health system. This report tackles the growing market interest in pharmacogenomics, companion diagnostics and the associated market environment. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analysed. This study reveals market figures of the overall personalized medicine market and also sub-market figures. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial and product review of key players in the personalized medicine industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. In summary, the personalized medicine and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: Executive Summary Introduction Personalized Medicine Therapeutics and Companion Diagnostics Personalized Medicine and Integration into the Healthcare System Private and Public Funding and Personalized Medicine Reimbursement European Personalized Medicine Market - Payments and Investment Personalized Medicine -Business Model Analysis Personalized Medicine Main Industry Players Personalized Medicine Industry Products and Kits Personalized Medicine Market Analysis Strengths and Advantages of Personalized Medicine Restraints of the Personalized Medicine Market Personalized Medicine and Regulatory Policies Final Summary and Future Perspectives List of Tables List of Figures Companies Mentioned - 23andMe - Affymetrix - Astex Pharmaceuticals - Atossa Genetics - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Illumina - Genelex - Myriad - Nodality - Qiagen For more information visit http://www.researchandmarkets.com/research/s6...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Astex Pharmaceuticals to Present at AACR-NCI-EORTC
GlobeNewswire - Mon Oct 14, 3:30PM CDT
Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced four presentations of developmental and collaboration programs will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 20 and 21, in Boston.
Otsuka Pharmaceutical Co Ltd acquires Astex Pharmaceuticals for USD8.50 per share
M2 - Mon Oct 14, 5:50AM CDT
Otsuka Holdings Co Ltd reported on Friday the completion of the acquisition of Astex Pharmaceuticals Inc (NasdaqGS:ASTX) for USD8.50 per share, net to the seller in cash, without interest and less any required withholding taxes.
Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals
Business Wire - Fri Oct 11, 7:31AM CDT
Otsuka Holdings Co., Ltd. ("Otsuka Holdings") announced today that its wholly-owned subsidiary, Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"), successfully completed, through its wholly-owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex") for US $8.50 per share, net to the seller in cash, without interest and less any required withholding taxes. The acquisition was effected through a tender offer ("Tender Offer"), which was commenced on September 13, 2013, New York time and expired at 12:00 midnight, New York time at the end of October 10, 2013, followed by a merger on October 11, 2013.
Astex Pharmaceuticals Responds to Further Misleading Claims Made by Sarissa Capital
GlobeNewswire - Wed Oct 09, 9:37PM CDT
Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, issued the following statement in response to further misleading claims made by Sarissa Capital in a press release issued earlier today:
Sarissa Capital Highlights Advancement Of Astex Pipeline Compound
PR Newswire - Wed Oct 09, 4:27PM CDT
Sarissa Capital today issued the following open letter to shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX):
Sarissa Capital Urges All Shareholders Of Astex Pharmaceuticals To Not Tender Their Shares At Current $8.50 Price
PR Newswire - Tue Oct 08, 12:33PM CDT
Sarissa Capital today issued the following open letter to shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX):
Astex Pharmaceuticals Announces Expiration of HSR Waiting Period for Pending Transaction
GlobeNewswire - Mon Oct 07, 5:00AM CDT
Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), announced today that the waiting period for U.S. antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the previously announced acquisition of Astex by Otsuka Pharmaceutical Co., Ltd ("Otsuka"), expired on Friday, October 4, 2013. Expiration of the waiting period satisfies a condition to the closing of the tender offer by Otsuka for all of the outstanding shares of Astex common stock for $8.50 per share in cash, which is scheduled to expire at 12:00 AM ET on October 10, 2013, unless extended or earlier terminated. The closing of the tender offer remains subject to other customary closing conditions, including, among others, the tender into the offer by the holders of a majority of the outstanding shares of Astex.
